top of page

Prolonged response to metastatic pancreatic cancer treated with pembrolizumab based on mismatch repa

Prolonged response to metastatic pancreatic cancer treated with pembrolizumab based on mismatch repair status characterized from next generation sequencing

Lan Ngo


Comments


bottom of page